Latest Ratios: P/E Ratio -3.3x · EV/EBITDA N/A · ROE -136.2%. (2022–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Market Cap | $1.2B | $1.6B | $342M | — | — |
| Enterprise Value | $1.2B | $1.6B | $23M | — | — |
| P/E Ratio → | -3.28 | — | — | — | — |
| P/S Ratio | 123.57 | 162.41 | 68.44 | — | — |
| P/B Ratio | 5.11 | 6.71 | 1.10 | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| EV / Revenue | — | 159.35 | 4.70 | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | -2682.8% | 100.0% | — |
| Operating Margin | -2113.8% | -2113.8% | -3277.8% | -74.3% | — |
| Net Profit Margin | -3777.4% | -3777.4% | -3139.8% | -74.2% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| ROE | -136.2% | -136.2% | -362.0% | — | — |
| ROA | -100.2% | -100.2% | -71.7% | -52.0% | -159.9% |
| ROIC | -154.5% | -154.5% | — | — | — |
| ROCE | -66.7% | -66.7% | -91.7% | -79.4% | -156.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Debt / Equity | 0.33 | 0.33 | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | -0.13 | -1.02 | — | — |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | -50.56 | -50.56 | — | — | — |
Net cash position: cash ($111M) exceeds total debt ($80M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Current Ratio | 5.61 | 5.61 | 6.21 | 2.57 | 2.64 |
| Quick Ratio | 5.61 | 5.61 | 6.21 | 2.57 | 2.64 |
| Cash Ratio | 5.48 | 5.48 | 6.12 | 2.44 | 2.59 |
| Asset Turnover | — | 0.03 | 0.01 | 0.73 | — |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $45M | $42M | $38M | $38M |
Includes 30+ ratios · 4 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ZBIO stock.
Zenas BioPharma, Inc.'s current P/E ratio is -3.3x. This places it at the 50th percentile of its historical range.
Zenas BioPharma, Inc.'s return on equity (ROE) is -136.2%. The historical average is -249.1%.
Based on historical data, Zenas BioPharma, Inc. is trading at a P/E of -3.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Zenas BioPharma, Inc. has 100.0% gross margin and -2113.8% operating margin.